Header Logo

Connection

Kathleen Moore to Dasatinib

Back to Details
This is a "connection" page, showing publications Kathleen Moore has written about Dasatinib.
Kathleen Moore
Connection Strength
0.053
Dasatinib
  1. A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283. Gynecol Oncol. 2023 09; 176:16-24.
    View in: PubMed
    Score: 0.053
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.